Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bedaquiline safety and preliminary efficacy study in children with MDR/RR pulmonary tuberculosis
ChiCTR2000033611Phase 2Not yet recruiting
- Sponsor
- Shanghai Public Health Clinical Center
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bedaquiline in multidrug-resistant tuberculosis (MDR-TB), Tuberculosis (TB) and pulmonary tuberculosis (TB), sponsored by Shanghai Public Health Clinical Center. Primary endpoints: Adverse events and Negative conversion rate of sputum smear and sputum culture. Planned start Jun 2020; status: not yet recruiting.
02
Drugs
bedaquiline
03
Conditions
multidrug-resistant tuberculosis (MDR-TB)Tuberculosis (TB)pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on ChiCTR2000033611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000033611.